0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > B7-2

B7-2

B7-2 Molecule Information

Name:Cluster of Differentiation 86
Target Synonym:T-lymphocyte activation antigen CD86;FUN-1;CTLA-4 counter-receptor B7.2;CD86;B70;BU63;CD_antigen=CD86;Activation B7-2 antigen;CD28LG2
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:9
Lastest Research Phase:Approved

B7-2 Protein Product ListCompare or Buy

B7-2 Molecule Synonym Name

CD86,B7-2,B70,CD28LG2,LAB72,MGC34413

B7-2 Molecule Background

Cluster of Differentiation 86 (CD86) is also known as B-lymphocyte activation antigen B7-2, is a type I membrane protein that is a member of the immunoglobulin superfamily, and is constitutively expressed on interdigitating dendritic cells, Langerhans cells, peripheral blood dendritic cells, memory B cells, and germinal center B cells. Additionally, B72 is expressed at low levels on monocytes and can be upregulated through interferon ¦Ã. CD86 is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD86 works in tandem with CD80 to prime T cells. Recent study has revealed that B7-2 promotes the generation of a mature APC repertoire and promotes APC function and survival. Furthermore, the B7 proteins are also involved in innate immune responses by activating NF-¦ÊB-signaling pathway in macrophages. CD86 thus is regarded as a promising candidate for immune therapy. CD86+ macrophages in Hodgkin lymphoma patients are an independent marker for potential nonresponse to firstline-therapy.

B7-2 References

B7-2 Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Belatacept BMS-224818; LEA29Y; L104EA29YIg; LEA-029 Approved Bristol-Myers Squibb NULOJIX fda Rejection of organ transplantation BRISTOL MYERS SQUIBB 2011-06-15 Rejection of organ transplantation, Rejection of renal transplantation Details
Abatacept BMS-188667; ONO-4164; BMS-188667SC; ONO-4164SC,MS188667; ONO4164; BMS188667SC; ONO4164SC Approved Bristol-Myers Squibb, Ono Pharmaceutical ORENCIA fda Rheumatoid arthritis (RA), Juvenile rheumatoid arthritis (JRA) BRISTOL MYERS SQUIBB 2005-12-23 Juvenile idiopathic arthritis (JIA), Psoriatic arthritis, Rheumatoid arthritis (RA), Juvenile rheumatoid arthritis (JRA) Details

B7-2 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Immunogene therapy (Briana Bio-Tech) Phase Ⅰ University of Alberta, Briana Bio-tech Inc Glioma, Melanoma Details
Abatacept biosimilar (Momenta Pharmaceuticals) M-834 Phase Ⅰ Momenta, Mylan Autoimmune diseases, Immune-inflammatory diseases Details
Attenuated viral vector immunogene-based therapy and vaccine (Radient Pharmaceuticals) Phase Ⅰ Radient, Jaiva Technologies Cancer Details
Abatacept biosimilar (Hanwha Biologics) Phase Not Specified Hanwha Biologics Arthritis Details
Chimeric antigen receptor T-cell therapy (Hunan Zhaotai Yongren Biotech) Z-CTLs Phase Ⅰ Hunan Zhaotai Yongren Biotech Non small cell lung cancer (NSCLC) Details
Recombinant human CTLA4-Ig Fusion protein(Shanghai CP Guojian) Phase Ⅰ Shanghai CP Guojian Rheumatoid arthritis (RA) Details
APVO-210 APVO-210; ES-210 Phase Ⅰ Aptevo Ulcerative colitis, Psoriasis Details
ASP-2408 ASP-2408 Phase Ⅰ Maxygen, Astellas Rheumatoid arthritis (RA) Details
CTLA-4/FasL fusion protein (KAHR Medical) KAHR-102 IND Filing KAHR Medical Lymphoma Details

This web search service is supported by Google Inc.

totop